Drug intelligence / Profile preview

CAN107

Development stage: Preclinical
Lead developer: CANbridge Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CAN107 is a monoclonal antibody that functions as a fibroblast growth factor 23 (FGF23) antagonist. It is being developed by CANbridge Life Sciences and its affiliates for the treatment of X-linked hypophosphatemia (XLH) and related hypophosphatemic disorders. The drug works by blocking FGF23, a hormone involved in phosphate regulation, thereby addressing the underlying cause of low phosphate levels seen in XLH and similar conditions. As of June 2025, CAN107 remains in preclinical development[1][2].

Targets

FGF23 (Fibroblast growth factor 23)

Beyond the preview

Go deeper on CAN107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAN107.

Explore the full profile